Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10485150 | Value in Health | 2012 | 7 Pages |
Abstract
Switch maintenance with pemetrexed in patients with advanced nonsquamous-cell lung cancer after standard first-line chemotherapy is not cost-effective. Uncertainties on the resource use and costs for BSC have a large influence on the cost-effectiveness calculation and should be reported in more detail.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Klazien PhD, Markus MD, Ursula Kühnel, Thomas PhD, Bernhard PhD, MD, Matthias PhD,